GEP20022647B - Synergistic Combinations - Google Patents

Synergistic Combinations

Info

Publication number
GEP20022647B
GEP20022647B GEAP19963898A GEAP1996003898A GEP20022647B GE P20022647 B GEP20022647 B GE P20022647B GE AP19963898 A GEAP19963898 A GE AP19963898A GE AP1996003898 A GEAP1996003898 A GE AP1996003898A GE P20022647 B GEP20022647 B GE P20022647B
Authority
GE
Georgia
Prior art keywords
cis
amino
derivative
oxathiolan
pyrimidin
Prior art date
Application number
GEAP19963898A
Other languages
English (en)
Inventor
Clair Martha Heider St
David Walter Barry
Original Assignee
The Wellcome Foundation Ltd Gb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20022647(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by The Wellcome Foundation Ltd Gb filed Critical The Wellcome Foundation Ltd Gb
Publication of GEP20022647B publication Critical patent/GEP20022647B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cephalosporin Compounds (AREA)
GEAP19963898A 1995-03-30 1996-03-28 Synergistic Combinations GEP20022647B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations

Publications (1)

Publication Number Publication Date
GEP20022647B true GEP20022647B (en) 2002-03-25

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP19963898A GEP20022647B (en) 1995-03-30 1996-03-28 Synergistic Combinations

Country Status (35)

Country Link
US (1) US6417191B1 (Direct)
EP (1) EP0817637B1 (Direct)
JP (1) JP2954357B2 (Direct)
KR (1) KR100542536B1 (Direct)
CN (1) CN1103593C (Direct)
AP (1) AP652A (Direct)
AT (1) ATE220551T1 (Direct)
AU (1) AU715213B2 (Direct)
BR (3) BRPI9607851B8 (Direct)
CA (1) CA2216634C (Direct)
CZ (1) CZ295940B6 (Direct)
DE (3) DE69622386T2 (Direct)
DK (1) DK0817637T3 (Direct)
EA (1) EA000626B3 (Direct)
EE (1) EE04047B1 (Direct)
ES (1) ES2179193T3 (Direct)
FR (1) FR05C0022I2 (Direct)
GE (1) GEP20022647B (Direct)
HU (1) HU224010B1 (Direct)
IL (1) IL117727A (Direct)
LU (1) LU91171I2 (Direct)
MX (1) MX9707316A (Direct)
MY (1) MY115461A (Direct)
NL (1) NL300195I2 (Direct)
NO (2) NO313787B1 (Direct)
NZ (1) NZ306419A (Direct)
OA (1) OA10616A (Direct)
PL (1) PL187085B1 (Direct)
PT (1) PT817637E (Direct)
RO (1) RO117995B1 (Direct)
SI (1) SI0817637T1 (Direct)
SK (1) SK283825B6 (Direct)
TR (1) TR199701074T1 (Direct)
UA (1) UA60293C2 (Direct)
WO (1) WO1996030025A1 (Direct)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
PE74799A1 (es) * 1997-05-17 1999-08-13 Glaxo Group Ltd Combinaciones antivirales
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
CA2512475C (en) 2003-01-14 2009-06-02 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
ATE490470T1 (de) 2003-10-24 2010-12-15 Immunaid Pty Ltd Therapieverfahren
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
WO2008071587A2 (en) 2006-12-13 2008-06-19 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
KR101964923B1 (ko) 2010-01-27 2019-04-02 비이브 헬쓰케어 컴퍼니 항바이러스 치료
MX2016002560A (es) 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
TW201622731A (zh) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 包含恩曲他濱（Ｅｍｔｒｉｃｉｔａｂｉｎｅ）、替諾福韋（Ｔｅｎｏｆｏｖｉｒ）、地瑞那韋（Ｄａｒｕｎａｖｉｒ）及利托那韋（Ｒｉｔｏｎａｖｉｒ）之單位劑型以及包含地瑞那韋及利托那韋之單層錠劑
JP6749890B2 (ja) 2014-08-12 2020-09-02 モナッシュ ユニバーシティ リンパ指向プロドラッグ
EP3347340A4 (en) 2015-09-08 2019-01-23 Monash University LYMPHENLEITUNGSPRODRUGS
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP4306524A3 (en) * 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
IL295362A (en) 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid prodrugs of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
ES2083668T5 (es) 1991-05-16 2001-06-16 Glaxo Group Ltd Combinaciones antiviricas que contienen analogos de nucleosido.
AU4079593A (en) 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
CA2262765A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
CN1103593C (zh) 2003-03-26
NO974510D0 (no) 1997-09-29
EP0817637A1 (en) 1998-01-14
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
ES2179193T3 (es) 2003-01-16
PL322532A1 (en) 1998-02-02
DK0817637T3 (da) 2002-11-11
KR19980703420A (ko) 1998-11-05
DE122005000029I2 (de) 2006-04-27
IL117727A0 (en) 1996-07-23
BRPI9607851B8 (pt) 2019-11-05
NO2005014I1 (no) 2005-06-06
AU715213B2 (en) 2000-01-20
ATE220551T1 (de) 2002-08-15
JP2954357B2 (ja) 1999-09-27
KR100542536B1 (ko) 2006-03-23
CN1185110A (zh) 1998-06-17
EP0817637B1 (en) 2002-07-17
EA199700203A1 (ru) 1998-02-26
BR9607851B1 (pt) 2009-01-13
CZ309097A3 (cs) 1998-05-13
HU224010B1 (hu) 2005-04-28
HUP9801571A3 (en) 2001-04-28
NL300195I2 (nl) 2005-11-01
AP652A (en) 1998-06-19
JPH10511682A (ja) 1998-11-10
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
CA2216634A1 (en) 1996-10-03
CA2216634C (en) 2004-07-20
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
OA10616A (en) 2001-03-15
FR05C0022I1 (Direct) 2005-06-10
AP9701089A0 (en) 1997-10-31
RO117995B1 (ro) 2002-12-30
CZ295940B6 (cs) 2005-12-14
EE04047B1 (et) 2003-06-16
BRPI9612992B1 (pt) 2020-08-04
HK1009401A1 (en) 1999-09-10
EA000626B3 (ru) 2016-04-29
UA60293C2 (uk) 2003-10-15
US6417191B1 (en) 2002-07-09
MX9707316A (es) 1997-11-29
EE9700240A (et) 1998-04-15
DE122005000029I1 (de) 2005-10-06
NO2005014I2 (no) 2008-02-11
LU91171I9 (Direct) 2018-12-28
MY115461A (en) 2003-06-30
LU91171I2 (fr) 2005-07-04
AU5497296A (en) 1996-10-16
SK129597A3 (en) 1998-07-08
DE69622386T2 (de) 2003-02-13
FR05C0022I2 (Direct) 2005-10-21
SI0817637T1 (en) 2002-10-31
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
NO313787B1 (no) 2002-12-02
IL117727A (en) 1999-11-30
NO974510L (no) 1997-09-29
PL187085B1 (pl) 2004-05-31
EA000626B1 (ru) 1999-12-29
BR9607851A (pt) 1998-07-21

Similar Documents

Publication Publication Date Title
GEP20022647B (en) Synergistic Combinations
NO20053817L (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
TW366346B (en) 1,3-oxathiolane nucleoside analogue
BR0214806A (pt) Composições farmacêuticos de 5,7,14-triazatetraciclo-{10.3.1.02,11.0,4,9]-hexadeca-2(1 1),3,5,7,9-penteno
BR9406893A (pt) Emprego de nona- e decapeptideos para a preparação de um medicamento para o combate da aids
BR0311701A (pt) Formulação de dosagem multiparticulada com liberação controlada de lamotrigina, composição farmacêutica, processo para a preparação de uma composição farmacêutica de lamotrigina, método para a redução da flutuação no pico e no depósito da concentração da droga no plasma do sangue de um paciente, método para melhorar a complacência de um paciente pela redução da frequência de dosagem para uma vez por dia, método para a ministração mais segura de lamotrigina, método para proporcionar uma concentração terapêutica de plasma de sangue de lamotrigina e uso da formulação
BR9712610A (pt) Composições farmacêutica e liquida, uso de aciclovir ou de um derivado do mesmo farmaceuticamente aceitável, processo para preparação de uma composição, e, disportivo de aplicação tópica.
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
AP9801419A0 (en) Combination comprising VX478, zidovudine, FTC and or 3
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
YU47799A (sh) Farmaceutski preparati
ES2130246T3 (es) Nucleosidos terapeuticos de la serie 2',3'-didesoxi-3'-fluoro-purina.
AR002957A1 (es) Una combinacion de compuestos utiles, su uso para preparar un medicamento, y una composicion y combinacion farmaceutica que los contienen.
BRPI0415322A (pt) composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
AR040242A1 (es) Composiciones farmaceuticas
AR043332A1 (es) Composiciones y metodos para terapia antiviral
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
AR026255A1 (es) Combinaciones antivirales.
ES2189964T3 (es) Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.
AR017455A1 (es) Composiciones farmaceuticas que comprenden (1s,4r)-cis-4-[2-amino-6-ciclopropilamino)-9h-purin-9-ilo]-2-ciclopenten-1-metanol, un quelante de metal y un agente edulcorante
ATE162401T1 (de) Antivitale zusammensetzungen
Green Alimta (pemetrexed disodium): a multitargeted antifolate for the treatment of mesothelioma
WO2000018383A3 (en) Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester
AR040805A1 (es) Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral
Gilden Three drugs now in expanded access